PIRIMIDINAS COMO ANTAGONISTAS DEL RECEPTOR DE PROSTAGLANDINA D2

La presente invención se refiere a un compuesto de Fórmula (I) (I)en la que Cy1, Cy2, L1, L2 y R1 son como se definen en este documento, a una composición farmacéutica que comprende una cantidad farmacéuticamente eficaz de uno o más compuestos de acuerdo con la Fórmula (I) en mezcla con un vehículo farmacéuticamente aceptable, a un método para tratar a un paciente que padece un trastorno mediado por la PGD2 incluyendo, pero sin limitación, asma bronquial, enfermedad pulmonar obstructiva crónica (COPD), rinitis alérgica, dermatitis alérgica, conjuntivitis alérgica, bronquitis, mastocitosis sistémica y lesión de reperfusión isquémica por medio de la administración a dicho paciente de una cantidad farmacéuticamente eficaz de un compuesto de acuerdo con la Fórmula (I). The present invention is directed to a compound of Formula (I) wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).